Amicus begins expanded access program

Amicus Therapeutics Inc. (NASDAQ:FOLD) began a reimbursed expanded access program for migalastat ( AT1001) to treat Fabry's disease. The program will begin in France, where the French National Agency for Medicines and Health Products Safety (ANSM) has granted an Authorization of Temporary Use (ATU) of the small molecule that enhances alpha galactosidase A activity.

Amicus said the program will be implemented in some territories where it can secure reimbursement prior to approval. ...